Remaining generally unchanged, urinary tract infection (UTI) treatment protocols require continuing monitoring due to growing antibiotic resistance and lowered immune status of the majority of patients. The article presents the results of a prospective observational program carried out the Russian Federation in to assess the effectiveness and safety of Ceforal(R), Solutab(R) and Uro-Vaksom(R) in patients with recurrent uncomplicated lower urinary tract infections (FLORA). The results of the program suggest that Ceforal(R) Solutab(R) and Uro-Vaksom(R) administered as a part of routine clinical practice contribute to a significant reduction in the number of UTI recurrences and have a good safety profile. These findings support recommendation to use this treatment protocol in patients with recurrent UTI, taking into account individual and epidemiological features.